CAR T Therapy Approval Highlights AJPB Week in Review

Top news of the week from The American Journal of Pharmacy Benefits.

5. Out-of-Pocket Expenses of Chronic Heart Disease Burdensome for Low-Income Families

Low-income families can experience catastrophic financial burden from cumulative out-of-pocket expenses for atherosclerotic cardiovascular disease treatments.

Click to read more.

4. AbbVie Seeks Approval for Moderate to Severe Plaque Psoriasis Drug

Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.

Click to read more.

3. New Analysis Further Supports Canagliflozin

In an additional analysis from the CANVAS program, new data reinforce evidence of improved renal outcomes for those with type 2 diabetes and chronic kidney disease.

Click to read more.

2. Claims Data for Hereditary Angioedema Drugs Show Need for Use Management

Half of all HAE drug expenses were billed through the pharmacy benefit and half through the medical benefit

Click to read more.

1. FDA Approves CAR T-Cell Therapy for Large B-Cell Lymphoma

The approval includes the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Click to read more.